Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-08-2009 | Original Article

Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma

Authors: Alida C. Fröberg, Marion de Jong, Berthold A. Nock, Wout A. P. Breeman, Jack L. Erion, Theodosia Maina, Marion Verdijsseldonck, Wouter W. de Herder, Aad van der Lugt, Peter P. M. Kooij, Eric P. Krenning

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2009

Abstract

Purpose

Cholecystokinin 2 (CCK-2) receptor overexpression has been demonstrated in a high percentage of medullary thyroid carcinomas (MTC). Analogous to somatostatin receptors, CCK-2 receptors might be viable targets for radionuclide scintigraphy and/or radionuclide therapy. Several CCK-2 receptor-binding radiopeptides have been developed, and some have been carried through into clinical studies. However, these studies are mostly limited and difficult to compare. The aim of this study was to evaluate the diagnostic and therapeutic potential of three promising CCK-2 receptor-binding radiopeptides in patients with MTC.

Methods

¹¹¹In-DOTA-(D)Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH₂ (¹¹¹In-DOTA-CCK), a CCK analogue, and the gastrin-based ligands ^99mTc-N₄-Gly-(D)Glu-(Glu)₅-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH₂ (^99mTc-demogastrin 2) and ¹¹¹In-DOTA-(D)Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH₂ (¹¹¹In-DOTA-MG11) were each administered to the same group of six patients. Planar images made at 3–5, 7 and 24 h p.i. were used for comparison of tumour visualisation and renal uptake.

Results

^99mTc-demogastrin 2 scintigraphy visualised all known lesions and new lesions in four of six patients. ¹¹¹In-DOTA-CCK and ¹¹¹In-DOTA-MG11 on the other hand missed several lesions; tumour uptake of these two radiopharmaceuticals was quite low. Comparison of retention of renal activity showed no major differences between the three radiopeptides.

Conclusion

^99mTc-demogastrin 2 scintigraphy appeared most promising as a diagnostic tool in patients with MTC. Further studies are required to evaluate its value in patient management. Direct comparisons of the compounds studied strongly suggests that ¹¹¹In-DOTA-CCK and ¹¹¹In-DOTA-MG11 have less potential as imaging agents than ^99mTc-demogastrin 2. These DOTA-linked compounds are considered unlikely to be useful for radionuclide therapy because of low tumour uptake.

Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 1996;67:644–7. doi:10.1002/(SICI)1097–0215(19960904)67:5<644::AID-IJC9>3.0.CO;2-U.PubMedCrossRef

Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with (111In-DTPA-D-Phe1)-and (123I-Tyr3-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–31. doi:10.1007/BF00181765.PubMedCrossRef

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:62S–6S.PubMed

Behr TM, Jenner N, Béhé M, Angerstein C, Gratz S, Raue F, et al. Radiolabelled peptides for targeting of cholecystokinin-B/gastrin receptor expressing tumours: from preclinical development to initial clinical results. J Nucl Med 1999;40:1029–44.PubMed

Béhé M, Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 2002;66:399–418. doi:10.1002/bip.10356.PubMedCrossRef

Gotthardt M, Béhé MP, Beuter D, Battmann A, Bauhofer A, Schurrat T, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2006;33:1273–9. doi:10.1007/s00259–006–0157–8.PubMedCrossRef

Nock BA, Maina T, Béhé M, Nikolopoulou A, Gotthardt M, Schmitt JS, et al. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin anologs. J Nucl Med 2005;46:1727–36.PubMed

Kwekkeboom DJ, Bakker WH, Kooij PPM, Erion J, Srinivasan A, De Jong M, et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 2000;27:1312–7. doi:10.1007/s002590000296.PubMedCrossRef

Béhé M, Reubi J, Nock B, Mäcke H, Breeman WAP, Bernard HF, et al. Evaluation of a DOTA-minigastrin derivative for therapy and diagnosis for CCK-2 receptor positive tumours. Eur J Nucl Med Mol Imaging 2005;32 Suppl 1:S78.

10.

Breeman WAP, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003;30:917–20.PubMed

11.

Breeman WAP, Fröberg AC, de Blois E, van Gameren A, Melis M, de Jong M, et al. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. Nucl Med Biol 2008;35:839–49. doi:10.1016/j.nucmedbio.2008.09.006.PubMedCrossRef

12.

Reubi JC, Waser B, Läderach U, Stettler C, Friess H, Halter F, et al. Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology 1997;112:1197–205. doi:10.1016/S0016–5085(97)70131–8.PubMedCrossRef

13.

Gotthardt M, Béhé MP, Grass J, Bauhofer A, Rinke A, Schipper M, et al. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer 2006;13:1203–11. doi:10.1677/erc.1.01245.PubMedCrossRef

14.

Cox JD. Moss’ radiation oncology: rationale, technique, results. St. Louis: Mosby; 1994. p. 290–295.

15.

Good S, Walter MA, Waser B, Wang X, Müller-Brand J, Béhé MP, et al. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging 2008;35:1868–77. doi:10.1007/s00259–008–0803–4.PubMedCrossRef

16.

de Jong M, Bakker WH, Bernard BF, Valkema R, Kwekkeboom DJ, Reubi JC, et al. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 1999;40:2081–7.PubMed

17.

Béhé M, Kluge G, Becker W, Gotthardt M, Behr TM. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 2005;46:1012–5.PubMed

18.

Gotthardt M, van Eerd-Vismale J, Oyen WJG, de Jong M, Zhang H, Rolleman E, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 2007;48:596–601. doi:10.2967/jnumed.106.036020.PubMedCrossRef

Title: Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma
Authors: Alida C. Fröberg
Marion de Jong
Berthold A. Nock
Wout A. P. Breeman
Jack L. Erion
Theodosia Maina
Marion Verdijsseldonck
Wouter W. de Herder
Aad van der Lugt
Peter P. M. Kooij
Eric P. Krenning
Publication date: 01-08-2009
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-009-1098-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2009

Metaiodobenzylguanidine (mIBG) molecular imaging in implantable cardioverter defibrillator (ICD) therapy planning: a health technology assessment issue

Influence of multidrug resistance on 18F-FCH cellular uptake in a glioblastoma model

Characterization of preclinical models of prostate cancer using PET-based molecular imaging

18F-FDG PET for the evaluation of thymic epithelial tumors: Correlation with the World Health Organization classification in addition to dual-time-point imaging

EANM guidelines for ventilation/perfusion scintigraphy

Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics